306 results on '"Chuong, Michael D."'
Search Results
2. PTCOG Gastrointestinal Subcommittee Lower Gastrointestinal Tract Malignancies Consensus Statement
3. Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastases
4. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study
5. Commissioning Intracranial Stereotactic Radiosurgery for a Magnetic Resonance-Guided Radiation Therapy (MRgRT) System: MR-RT Localization and Dosimetric End-to-End Validation
6. Dosimetric comparison of magnetic resonance-guided radiation therapy, intensity-modulated proton therapy and volumetric-modulated arc therapy for distal esophageal cancer
7. Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas
8. MRI-Guided Adaptive Radiation Therapy
9. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer
10. Online adaptive radiotherapy: Assessment of planning technique and its impact on longitudinal plan quality robustness in pancreatic cancer
11. Neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable pancreas adenocarcinoma: influence of vascular margin status and type of chemotherapy
12. Quality assurance of an established online adaptive radiotherapy program: patch and software upgrade
13. In Reply to Cellini and Fiore
14. Advances in MRI-Guided Radiation Therapy
15. Racial disparities in clinical presentation, surgical procedures, and hospital outcomes among patients with hepatocellular carcinoma in the United States
16. Accelerated hypofractionated magnetic resonance-guided adaptive radiotherapy for oligoprogressive non-small cell lung cancer
17. Treatment of glioblastoma using MRIdian® A3i BrainTx™: Imaging and treatment workflow demonstration
18. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States – Understanding the transition to adaptive, ultra-hypofractionated treatments
19. The First Report of Using Low-Field MRI-Guided Radiation Therapy in a Patient With a Cochlear Implant
20. Clinical application of an institutional fractionated stereotactic radiosurgery (FSRS) program for brain metastases delivered with MRIdianⓇ BrainTx™
21. Trials and Technology to Advance Upper Gastrointestinal Oncology: Imagination, Imaging, and the Intertwined Imperfections
22. PD-1 inhibition combined with intensity-modulated radiotherapy, to better serve patients with retroperitoneal lymph node metastases from gastrointestinal cancer
23. Relationship between insurance status and interhospital transfers among cancer patients in the United States
24. Hospitalization rates from radiotherapy complications in the United States
25. Adaptive Radiation Therapy Physician Guidelines: Recommendations From an Expert Users’ Panel
26. Boosting the Abscopal Effect Using Immunogenic Biomaterials With Varying Radiation Therapy Field Sizes
27. Accelerated Hypofractionated Magnetic Resonance Guided Adaptive Radiation Therapy for Ultracentral Lung Tumors
28. Abstract A005: A multi-institutional randomized phase III trial of chemotherapy alone versus chemotherapy and ablative 5-fraction MRI-guided adaptive radiation therapy for locally advanced pancreatic cancer (LAP-ABLATE)
29. Abstract A004: Lymphopenia and spleen dose for inoperable pancreatic cancer patients receiving ablative 5-fraction radiation therapy
30. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study
31. Dosimetric comparison of magnetic resonance-guided radiation therapy, intensity-modulated proton therapy and volumetric-modulated arc therapy for distal esophageal cancer
32. A Comprehensive Analysis of a Prospective Multidisciplinary Peer Review Process Before Radiation Therapy Simulation
33. Ablative 5-Fraction Stereotactic Magnetic Resonance–Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer
34. AAPM Medical Physics Practice Guideline 14.a: Yttrium‐90 microsphere radioembolization.
35. Hospitalization rates for complications due to systemic therapy in the United States
36. AAPM Medical Physics Practice Guideline 14.a: Yttrium‐90 microsphere radioembolization
37. Commissioning Intracranial Stereotactic Radiosurgery for a Magnetic Resonance-Guided Radiation Therapy (MRgRT) System: MR-RT Localization and Dosimetric End-to-End Validation
38. Advanced and emerging radiation therapy approaches for intrahepatic cholangiocarcinoma
39. Mid/Distal Esophageal Cancer and Gastroesophageal Junction Cancer (Siewert Type I and II)
40. Rectal Cancer Update: Which Treatment Effects Are the Least "Brutal"?
41. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma.
42. Proton Beam Therapy and Photon-Based Magnetic Resonance Image-Guided Radiation Therapy: The Next Frontiers of Radiation Therapy for Hepatocellular Carcinoma.
43. Radiation Therapy for Borderline Resectable Pancreas Cancer: More to Come or Yesterday's News?
44. Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee
45. Hits and Misses in Novel Pancreatic and Rectal Cancer Treatment Options
46. Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer
47. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings
48. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer
49. Initial clinical experience with magnetic resonance-guided radiotherapy in pediatric patients: Lessons learned from a single institution with proton therapy
50. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.